ADVANCING A NOVEL CANCER MEDICINE TO FILL A SIGNIFICANT TREATMENT GAP

Pacritinib is an investigational drug with a unique MOA that has the potential to help patients with cytopenic myelofibrosis who have limited treatment options.
Learn More
;

PACIFICA:
An Ongoing Phase 3 Trial

Pacritinib is currently being evaluated compared to physicians’ choice therapy in myelofibrosis patients with severe thrombocytopenia.
See Clinical Trials

Measuring Success in Terms of Our Impact on Patients

Join our team to advance new medicines that make a difference to patients.
See Open Positions